Wuhan Hvsen Biotechnology Co Ltd Capital Reinvestment Ratio
Wuhan Hvsen Biotechnology Co Ltd capital reinvestment ratio. Wuhan Hvsen Biotechnology Co Ltd (300871) has a Capital Reinvestment Ratio of 0.32x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥59.06 Million) in capital expenditures (CN¥18.73 Million). Check 300871 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Wuhan Hvsen Biotechnology Co Ltd (2016–2025)
Capital reinvestment ratio of Wuhan Hvsen Biotechnology Co Ltd from 2016 to 2025. This chart tracks Wuhan Hvsen Biotechnology Co Ltd's Capital Reinvestment Ratio across 10 annual periods. Also explore net asset growth rate of Wuhan Hvsen Biotechnology Co Ltd to track the company's year-over-year net asset growth rate.
Wuhan Hvsen Biotechnology Co Ltd Capital Reinvestment Ratio by Year (2016–2025)
Wuhan Hvsen Biotechnology Co Ltd capital reinvestment ratio by year from 2016 to 2025. For the full cash flow conversion analysis, see 300871 cash flow metrics.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.41x | CN¥238.45 Million | CN¥96.92 Million | ▼ -90.9% |
| 2024 | 4.47x | CN¥43.53 Million | CN¥194.43 Million | ▲ +125.2% |
| 2023 | 1.98x | CN¥92.92 Million | CN¥184.31 Million | ▼ -55.3% |
| 2022 | 4.44x | CN¥96.68 Million | CN¥428.87 Million | ▲ +15.1% |
| 2021 | 3.85x | CN¥155.72 Million | CN¥600.12 Million | ▼ -19.3% |
| 2020 | 4.77x | CN¥48.35 Million | CN¥230.84 Million | ▲ +308.3% |
| 2019 | 1.17x | CN¥105.24 Million | CN¥123.06 Million | ▼ -27.6% |
| 2018 | 1.61x | CN¥21.10 Million | CN¥34.05 Million | ▲ +130.6% |
| 2017 | 0.70x | CN¥80.56 Million | CN¥56.40 Million | ▲ +50.2% |
| 2016 | 0.47x | CN¥60.00 Million | CN¥27.97 Million | — |